ArticleBMJ paediatrics open2025
Antibodies against SARS-CoV-2 in children and adolescents: a one-year longitudinal study.
Article in BMJ paediatrics open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe humoral response to SARS-CoV-2 is not fully understood, especially in children. This study provides valuable insights into the durability of adaptive immunity in paediatric patients who were unvaccinated and naturally infected with the prototype strain of SARS-CoV-2, including those who were asymptomatic or had pre-existing chronic and rare disorders. This study aimed to analyse the antibody response to SARS-CoV-2 during infection and over a 1-year follow-up period in patients aged 0-18 years who were admitted to a tertiary paediatric hospital at the onset of the COVID-19 pandemic.
methodsThis is a descriptive, prospective 1-year cohort study carried out in children and adolescents hospitalised for different reasons from July to October 2020 who presented with SARS-CoV-2 infection. Clinical and serological data (total antibody pool) were collected during SARS-CoV-2 infection and throughout the subsequent year.
resultsDuring the study period, 122 patients with confirmed SARS-CoV-2 infection were included. Most patients (85%) had at least one serology assessed and reactive throughout 1-year follow-up, even those with asymptomatic infection or immunosuppressive conditions. The mean antibody titre levels reached their maximum value about 60 days after the initial SARS-CoV-2 infection. By the end of the 1-year follow-up, 72.46% of the 69 assessed individuals still had detectable serum antibodies. Patients with comorbidities and/or immunosuppression conditions had lower median titre levels over the year. Subjects with severe clinical presentation of COVID-19 had higher levels of antibody values at the 1-year time point assessment.
conclusionsThis study demonstrated that most subjects presented antibody response against SARS-CoV-2 over 1 year of follow-up, even if they had asymptomatic infection or comorbidities, including patients with immunosuppression. There was a difference in the magnitude and duration of antibody response, lower in patients with comorbidities and longer and higher in subjects who had severe COVID-19 clinical presentation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.